Crowley John F's Form 4 filing
Intellia Therapeutics, Inc. (NTLA) · filed Oct 7, 2021
- Accession no.
- 0001209191-21-059960
- Filed
- Oct 7, 2021
- Trade date
- Oct 5, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.31M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crowley John FCIK 0001400973 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2021 | Common Stock | MOption exerciseAcquired | +10,000 | $18.83 | +$188,300 | 12,094 | Direct | |
| Oct 5, 2021 | Common Stock | SSaleDisposed | −1,280 | $128.83F2 | −$164,902.4 | 10,814 | Direct | |
| Oct 5, 2021 | Common Stock | SSaleDisposed | −2,915 | $129.88F3 | −$378,600.2 | 7,899 | Direct | |
| Oct 5, 2021 | Common Stock | SSaleDisposed | −3,759 | $130.92F4 | −$492,128.28 | 4,140 | Direct | |
| Oct 5, 2021 | Common Stock | SSaleDisposed | −1,846 | $131.74F5 | −$243,192.04 | 2,294 | Direct | |
| Oct 5, 2021 | Common Stock | SSaleDisposed | −200 | $132.84 | −$26,568 | 2,094 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2021 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 28,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.09 to $129.05, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.28 to $130.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.445 to $131.42, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.445 to $132.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
Referenced by the price of 1 transaction in Table I.